Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13334457 | 0.94 | CCR5 (0.65) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13334518 | 0.94 | CCR5 (0.74) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13334545 | 0.92 | CCR5 (0.74) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL3324309 | 0.92 | CCR5 (0.73) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14679206 | 0.89 | CCR5 (0.57) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13334539 | 0.89 | CCR5 (0.76) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL13334648 | 0.89 | CCR5 (0.68) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13334536 | 0.88 | CCR5 (0.65) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL3327031 | 0.87 | CCR5 (0.74) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13334520 | 0.87 | CCR5 (0.65) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367674-B2 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100120786-A1 | Piperazine Derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20090270336-A1 | Piperazine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270336-A1 | Piperazine derivatives | CCR5, CCR2, CXCR3 | CCR5 1/4885CHRM2 2498/4885CHRM1 2938/4885 |
| US-20100120786-A1 | Piperazine Derivatives | CCR5, CCR2, CXCR3 | CCR5 1/4885CHRM2 2498/4885CHRM1 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.